


CLAIMS

1. A tartrate salt of Compound (I) represented by the following structural formula:



wherein the molar ratio between Compound (I) and tartaric acid is 1:1.

- 5 2. The tartrate salt of claim 1, wherein the tartrate salt is crystalline.
3. The tartrate salt of claim 1, wherein at least 90% by weight of the tartrate salt is in a single crystalline Form.
4. The tartrate salt of any one of claims 1-3, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which comprises peaks at 11.9°, 15.4°, 16.9°, and 17.2° ± 0.2 in 2θ.
- 10 5. The tartrate salt of any one of claims 1-3, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which comprises at least three peaks chosen from 11.9°, 15.4°, 16.9°, 17.2°, and 25.6° ± 0.2 in 2θ.
6. The tartrate salt of any one of claims 1-3, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which comprises peaks at 11.9°, 14.0°, 15.4°, 16.9°, 17.2°, 25.6°, 26.3, and 30.7° ± 0.2 in 2θ.
- 15 7. The tartrate salt of any one of claims 1-3, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which comprises peaks at 11.9°, 14.0°, 15.4°, 16.9°, 17.2°, 22.1°, 25.6°, 26.3, 30.7°, and 34.0° ± 0.2 in 2θ.
- 20 8. The tartrate salt of any one of claims 4-7, wherein the tartrate salt is characterized by an X-ray powder diffraction pattern which further comprises peaks at 8.7° and 12.9° ± 0.2 in 2θ.

9. The tartrate salt of any one of claims 1-8, wherein the tartrate salt is characterized by a differential scanning calorimeter (DSC) peak phase transition temperature of 189 ± 2 °C.
10. The tartrate salt of any one of claims 1-9, wherein water uptake is less than 4% of the mass of the tartrate salt at 90% relative humidity (RH) as measured under the following conditions:
- 5 i) drying between 0.5 and 1.5 mg of the tartrate salt under a nitrogen atmosphere at 0% relative humidity for 2 hours;
- 10 ii) increasing or decreasing the relative humidity in steps of 10% from 0% to 90% then to 0%;
- 15 iii) maintaining the relative humidity at each step until the mass change compared to the mass of the original tartrate salt per minute is less than 0.01 (%/min), provided that minimum and maximum duration time at each step is 10 minutes and 180 minutes, respectively; and
- iv) measuring the mass of the tartrate salt at 90% relative humidity and wherein steps i)-iv) are carried out at 25 °C.
11. The tartrate salt of claim 10, wherein water uptake is less than 1% of the mass of the tartrate salt at 90% relative humidity (RH).
12. The tartrate salt of any one of claims 1-11, wherein water uptake is less than 1% of the mass of the tartrate salt at 30% relative humidity (RH) as measured under following conditions:
- 20 i) drying between 0.5 and 1.5 mg of the tartrate salt under a nitrogen atmosphere at 0% relative humidity for 2 hours;
- 25 ii) increasing or decreasing the relative humidity in steps of 10% from 0% to 90% then to 0%;
- iii) maintaining the relative humidity at each step until the mass change compared to the mass of the original tartrate salt per minute is less than 0.01 (%/min), provided that minimum and maximum duration time at each step is 10 minutes and 180 minutes, respectively; and
- 30 iv) measuring the mass of the tartrate salt at 30% relative humidity and wherein steps i)-iv) are carried out at 25 °C.

13. The tartrate salt of claim 12, wherein water uptake is less than 0.1% of the mass of the tartrate salt at 30% relative humidity (RH).
14. A pharmaceutical composition comprising the tartrate salt of any one of claims 1-13, and a pharmaceutically acceptable carrier or diluent.
- 5 15. A method of treating a subject with cancer, comprising administering to the subject an effective amount of the tartrate salt of any one of claims 1-13 or the pharmaceutical composition of claim 14.
16. A method of treating a subject with cancer, comprising administering to the subject an effective amount of the tartrate salt of any one of claims 1-13 or the pharmaceutical composition of claim 14, and an effective amount of second anti-cancer treatment
10 (*e.g.*, a chemotherapeutic agent, a targeted therapeutic agent, radiation or surgery).
17. A method of treating a subject with cancer, comprising administering to the subject an effective amount of the tartrate salt of any one of claims 1-13 or the pharmaceutical composition of claim 14, and an effective amount of an immunomodulatory agent
15 such as a checkpoint inhibitor (*e.g.*, anti-PD-1 antibody, anti-CTLA4 antibody or anti-PD-L1 antibody) or an inhibitor of tryptophan oxidation (*e.g.* IDO1, IDO2 or TDO2 inhibitor).